Shorter blood thinner course after stents may cut bleeding risk

NCT ID NCT07374718

Not yet recruiting Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether heart attack patients with high bleeding risk can safely take blood thinners for only one month after a special drug-coated stent, instead of the usual 12 months. About 468 participants will be randomly assigned to the shorter or standard therapy. The goal is to see if the shorter plan reduces bleeding complications without increasing heart attacks or strokes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) followed by P2Y12 inhibitor monotherapy
What this could lead to: If successful, this could lead to a safer, shorter antiplatelet regimen that lowers bleeding risk without increasing heart attacks or strokes in high-risk patients.
What could go wrong: This is an early-stage trial with 468 participants, so results may not apply to all patients. The shorter therapy might not protect against ischemic events as well as standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME (ACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME (ACS) CORONARY ARTERY DISEASE (CAD) HIGH BLEEDING RISK(HBR)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

General Hospital of Northern Theater Command

Shenyang, Liaoning, 110000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.